

Presentation of the proposed Board

The Nomination Committee's proposal for the Board of Directors of BioArctic AB prior to the Annual General Meeting 2021

NEW ELECTION

Lotta Ljungqvist (1961)

Proposed as director:	2021
Holdings in BioArctic:	-
Education:	Ph.D Biochemical engineering, Royal Institute of Technology in Stockholm, Sweden.
Other current assignments:	Board member of Genovis AB, SciLifeLab, Atlas Antibodies AB and in Vinnova and SwedenBio.

Lotta Ljungqvist has a degree in biochemistry from the Royal Institute of Technology (KTH) and a doctorate in biochemical engineering. Lotta has more than 30 years of experience in the life science industry, where she has had several leading roles including CEO, business area manager responsible for sales and business development, research manager and project manager for biopharma projects. During her career, Lotta Ljungqvist has held positions at GE Healthcare Life Sciences, Biovitrum and Pharmacia and is currently CEO of Testa Center, Cytiva (formerly GE Healthcare Life Sciences). Her broad experience, industry knowledge and significant network will provide the Board with additional valuable expertise. Lotta Ljungqvist also has experience from board assignments in both public and private companies in the life science sector.

Lotta Ljungqvist is independent in relation to the company, its executive management and the major shareholders of the company.

RE-ELECTION

Wenche Rolfsen (1952)

Proposed chairman of the Board

Chairman since:	2017
Director since:	2016
Holdings in BioArctic:	47,175 B-shares
Education:	Pharmacist, Doctor of pharmacy (pharmacognosy), Adjunct Professor at Uppsala University, Sweden
Other current assignments:	Chairman of the Board of InDex Pharmaceuticals Holding AB. Board member of Swedish Match AB, and board member and CEO of Rolfsen Consulting AB. Partner in Serendipity Partners.

Wenche Rolfsen is independent in relation to the company, its executive management and the major shareholders of the company.

Ivar Verner (1947)

Deputy chairman since: 2017
Board member since: 2010
Holdings in BioArctic: 99,770 B-shares privately held and through Förvaltningsaktiebolaget Kanalen AB.
Education: Master of Business Administration, Stockholm School of Economics, Sweden
Other current assignments: Chairman of the Board of Erlandsons Brygga AB, Tegnér & Son AB and Valsättra Exploaterings AB. Board member of Sehlhall Fastigheter AB.

Ivar Verner is independent in relation to the company, its executive management and the major shareholders of the company.

Håkan Englund (1952)

Director since: 2020
Holdings in BioArctic: -
Education: Various courses in economics and chemistry from Uppsala University, Sweden. Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden.
Other current assignments: Chairman of the Board of SecureAppbox AB. Board member of Antrad Medical AB, Immuneed AB and Prostatype Genomics AB. Owner and CEO of JDS Invest AB.

Håkan Englund is independent in relation to the company, its executive management and the major shareholders of the company.

Pär Gellerfors (1947)

Director since: 2003
Holdings in BioArctic: 5,759,988 A-shares and 15,086,301 B-shares through Ackelsta AB.
Education: Bachelor's degree in chemistry; PhD in chemistry; Associate Professor of Biochemistry, all from Stockholm University, Sweden
Other current assignments: Board member of Ackelsta AB, LPB Sweden AB and Sigrid Therapeutics AB. Founder and CEO of MPG Medical AB.

Pär Gellerfors controls 23.7 percent of the share capital and 33.4 percent of the votes in the company and has previously been active in the company's management. Pär Gellerfors therefore is not independent in relation to the company, its executive management nor the major shareholders of the company.

Lars Lannfelt (1949)

Director since: 2003
Holdings in BioArctic: 8,639,998 A-shares and 22,628,052 B-shares through Demban AB.
Education: Physician; specialist in psychiatry and geriatrics; doctoral thesis; Associate Professor of Neurogenetics, all education and doctoral thesis at Karolinska Institutet Sweden; specialist in geriatrics.
Other current assignments: Board member of Demban AB and LPB Sweden AB. Senior Professor, Uppsala University.

Lars Lannfelt controls 35.5 percent of the share capital and 50.1 percent of the votes in the company and is employed in the company. Lars Lannfelt thereby is not independent in relation to the company, its executive management nor the major shareholders of the company.

Mikael Smedeby (1968)

Director since: 2018
Holdings in BioArctic: 37,270 B-shares
Education: Master of Laws, Uppsala University, Sweden
Other current assignments: Lawyer and Partner in the law firm Lindahl. Chairman of the board in Coeli Holding AB, Salléngruppen AB (incl. subsidiaries) and Navinci Diagnostics AB. Board member of Smedeby Förvaltning AB.

Mikael Smedeby is independent in relation to the company, its executive management and the major shareholders of the company.

Eugen Steiner (1954)

Director since: 2017
Holdings in BioArctic: 67,270 B-shares
Education: Medical doctor, Ph.D in clinical pharmacology from Karolinska Institutet, Sweden
Other current assignments: Chairman of the board of Spago Nanomedical AB and Empros Pharma AB. Board member in Apotek Produktion & Laboratorier AB, Inbox Capital AB, Karolinska Holdings AB, Stiftelsen Forska!Sverige and Stockholm School of Entrepreneurship. Partner in HealthCap.

Eugen Steiner is independent in relation to the company, its executive management and the major shareholders of the company.

The information regarding board assignments and holdings of shares is as of 31 December 2020 and also includes any changes thereafter known to the company.